Clarity is thrilled to announce that the first patient with metastatic prostate cancer to receive 2 doses of 8GBq of Cu-67 SAR-bisPSMA achieves undetectable PSA level. The patient was heavily pre-treated with multiple lines of therapy, including androgen deprivation therapy, ARPI, chemotherapy and a PARP inhibitor and had failed all previous treatments.
Sydney Angels Portfolio Company - Clarity Pharmaceuticals
